<p>NRx Pharmaceuticals（纳斯达克代码：NRXP - 获取免费报告）的股票在 D. Boral Capital 发布给客户和投资者的研究报告中重申了 “买入” 评级，Benzinga 报道。他们目前对该股票的目标价格为 34.00 美元。</p>
<ul>
<li>5 只生物科技股票满足未被满足的心理健康治疗需求</li>
</ul>
<p>其他几位研究分析师最近也对该公司发表了看法。Weiss Ratings 在 10 月 8 日的报告中重申了对 NRx Pharmaceuticals 股票的 “卖出（d-）” 评级。HC Wainwright 在 10 月 16 日的研究报告中重申了 “买入” 评级，并对 NRx Pharmaceuticals 股票设定了 40.00 美元的目标价格。Zacks Research 在 9 月 10 日的研究报告中将 NRx Pharmaceuticals 的评级上调至 “持有”。Ascendiant Capital Markets 在 10 月 30 日的研究报告中将 NRx Pharmaceuticals 的目标价格从 46.00 美元上调至 47.00 美元，并给予该股票 “买入” 评级。最后，Wall Street Zen 在 11 月 23 日的报告中将 NRx Pharmaceuticals 的评级从 “卖出” 上调至 “持有”。四位分析师对该股票给予了买入评级，一位给予了持有评级，一位给予了卖出评级。根据 MarketBeat 的数据，NRx Pharmaceuticals 目前的共识评级为 “适度买入”，平均目标价格为 34.75 美元。</p>
<p>获取 <strong>NRx Pharmaceuticals</strong> 的提醒：</p>
<p><strong>阅读我们关于 NRx Pharmaceuticals 的最新报告</strong></p>
<h2>NRx Pharmaceuticals 上涨 3.1%</h2>
<ul>
<li>你在做假日购物吗？这些股票可能是很好的礼物</li>
</ul>
<p>NRx Pharmaceuticals 的股票在周二的中午交易中上涨了 0.08 美元，达到了 2.47 美元。该股票交易了 244,367 股，而其平均交易量为 489,283 股。该公司的市值为 6926 万美元，市盈率为-1.04，贝塔值为 1.76。NRx Pharmaceuticals 的 12 个月低点为 1.15 美元，12 个月高点为 6.01 美元。该公司的 50 日简单移动平均为 2.86 美元，200 日简单移动平均为 2.89 美元。</p>
<p>NRx Pharmaceuticals（纳斯达克代码：NRXP - 获取免费报告）最近在 11 月 14 日发布了季度财报。该公司报告本季度每股收益为-0.18 美元，低于分析师共识预期的-0.11 美元，差距为-0.07 美元。该公司本季度的收入为 24 万美元，而分析师预期为 683 万美元。股票研究分析师预测，NRx Pharmaceuticals 在当前财政年度将发布-1.75 美元的每股收益。</p>
<h2>机构投资者对 NRx Pharmaceuticals 的看法</h2>
<p>几家机构投资者最近买入和卖出了 NRXP 的股票。Anson Funds Management LP 在第一季度将其在 NRx Pharmaceuticals 的持股增加了 535.1%。Anson Funds Management LP 现在拥有 1,179,061 股该公司的股票，价值 241.7 万美元，此前在上个季度增持了 993,401 股。Geode Capital Management LLC 在第二季度将其在 NRx Pharmaceuticals 的持股增加了 27.9%。Geode Capital Management LLC 现在拥有 172,255 股该公司的股票，价值 56.2 万美元，此前在此期间购买了 37,598 股。Ethos Financial Group LLC 在第三季度购买了 NRx Pharmaceuticals 的新股份，价值 39,000 美元。One Wealth Management Investment &amp; Advisory Services LLC 在第三季度将其在 NRx Pharmaceuticals 的持股增加了 86.1%。One Wealth Management Investment &amp; Advisory Services LLC 现在拥有 27,991 股该公司的股票，价值 92,000 美元，此前在上个季度增持了 12,950 股。最后，AdvisorShares Investments LLC 在第三季度将其在 NRx Pharmaceuticals 的持股增加了 29.7%。AdvisorShares Investments LLC 现在拥有 342,136 股该公司的股票，价值 112.9 万美元，此前在此期间增持了 78,339 股。目前，4.27% 的股票由对冲基金和其他机构投资者持有。</p>
<h2>关于 NRx Pharmaceuticals</h2>
<p>（获取免费报告）</p>
<p>NRx Pharmaceuticals, Inc 是一家临床阶段的生物制药公司，开发用于治疗中枢神经系统疾病的新型治疗药物，包括自杀性抑郁症、创伤后应激障碍和慢性疼痛。其产品包括 NRX-101（D-氨基酸/氟哌噻吨），这是一种口服固定剂量的 D-氨基酸和氟哌噻吨的组合，获得了食品和药物管理局指定的自杀治疗耐药性双相抑郁症的突破性疗法；以及 NRX-100（氯胺酮），该药物已获得 FDA 快速通道认证，用于治疗伴有急性自杀意念和行为的重度双相抑郁症。</p>
<h2>特色文章</h2>
<ul>
<li>五只我们更看好的股票超过 NRx Pharmaceuticals</li>
<li>8 月值得关注的三只最佳零售股票</li>
<li>这些是第三季度报告周期中最热门的升级</li>
<li>使用 MarketBeat 股息税计算器</li>
<li>Fossil 股票悄然上涨——内部人士刚刚进行了大额押注</li>
<li>ETF 筛选器：用途和逐步指南</li>
<li>为什么像 IBIT 这样的比特币 ETF 可能会在 2026 年激增</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TlJYUA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TlJYUA"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 NRx Pharmaceuticals 吗？</h2>
<p>在你考虑 NRx Pharmaceuticals 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 NRx Pharmaceuticals 并不在名单上。</p>
<p>虽然 NRX Pharmaceuticals 目前在分析师中被评为适度买入，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

NRXP

<p>D. Boral Capital 重申了对 NRX Pharmaceuticals 的 “买入” 评级，目标价为 34.00 美元。其他分析师的评级则各不相同，包括 “卖出”、“持有” 和 “买入”，平均目标价为 34.75 美元。该股票目前交易价格为 2.47 美元，上涨 3.1%。机构投资者已增加其持股，该公司专注于中枢神经系统疾病的治疗</p>

<p>NRx Pharmaceuticals (NASDAQ:NRXP - Get Free Report)'s stock had its &#34;buy&#34; rating restated by research analysts at D. Boral Capital in a research report issued to clients and investors on Tuesday,Benzinga reports. They presently have a $34.00 price objective on the stock.</p>
<div class="lb-trans"><p>NRx Pharmaceuticals（纳斯达克代码：NRXP - 获取免费报告）的股票在 D. Boral Capital 发布给客户和投资者的研究报告中重申了 “买入” 评级，Benzinga 报道。他们目前对该股票的目标价格为 34.00 美元。</p>
</div><ul>
<li>5 Biotech stocks tapping into unmet mental health treatment needs</li>
</ul>
<div class="lb-trans"><ul>
<li>5 只生物科技股票满足未被满足的心理健康治疗需求</li>
</ul>
</div><p>Several other research analysts also recently weighed in on the company. Weiss Ratings reiterated a &#34;sell (d-)&#34; rating on shares of NRx Pharmaceuticals in a report on Wednesday, October 8th. HC Wainwright reiterated a &#34;buy&#34; rating and issued a $40.00 target price on shares of NRx Pharmaceuticals in a research note on Thursday, October 16th. Zacks Research upgraded NRx Pharmaceuticals to a &#34;hold&#34; rating in a research report on Wednesday, September 10th. Ascendiant Capital Markets raised their price target on NRx Pharmaceuticals from $46.00 to $47.00 and gave the stock a &#34;buy&#34; rating in a research note on Thursday, October 30th. Finally, Wall Street Zen upgraded NRx Pharmaceuticals from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a report on Sunday, November 23rd. Four analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, NRx Pharmaceuticals currently has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $34.75.</p>
<div class="lb-trans"><p>其他几位研究分析师最近也对该公司发表了看法。Weiss Ratings 在 10 月 8 日的报告中重申了对 NRx Pharmaceuticals 股票的 “卖出（d-）” 评级。HC Wainwright 在 10 月 16 日的研究报告中重申了 “买入” 评级，并对 NRx Pharmaceuticals 股票设定了 40.00 美元的目标价格。Zacks Research 在 9 月 10 日的研究报告中将 NRx Pharmaceuticals 的评级上调至 “持有”。Ascendiant Capital Markets 在 10 月 30 日的研究报告中将 NRx Pharmaceuticals 的目标价格从 46.00 美元上调至 47.00 美元，并给予该股票 “买入” 评级。最后，Wall Street Zen 在 11 月 23 日的报告中将 NRx Pharmaceuticals 的评级从 “卖出” 上调至 “持有”。四位分析师对该股票给予了买入评级，一位给予了持有评级，一位给予了卖出评级。根据 MarketBeat 的数据，NRx Pharmaceuticals 目前的共识评级为 “适度买入”，平均目标价格为 34.75 美元。</p>
</div><p>Get <strong>NRx Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>NRx Pharmaceuticals</strong> 的提醒：</p>
</div><p><strong>Read Our Latest Report on NRx Pharmaceuticals</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 NRx Pharmaceuticals 的最新报告</strong></p>
</div><h2>NRx Pharmaceuticals Trading Up 3.1%</h2>
<div class="lb-trans"><h2>NRx Pharmaceuticals 上涨 3.1%</h2>
</div><ul>
<li>Doing Your Holiday Shopping? These Stocks Might Make Great Gifts</li>
</ul>
<div class="lb-trans"><ul>
<li>你在做假日购物吗？这些股票可能是很好的礼物</li>
</ul>
</div><p>Shares of NRx Pharmaceuticals stock traded up $0.08 during mid-day trading on Tuesday, hitting $2.47. 244,367 shares of the stock were exchanged, compared to its average volume of 489,283. The stock has a market capitalization of $69.26 million, a price-to-earnings ratio of -1.04 and a beta of 1.76. NRx Pharmaceuticals has a twelve month low of $1.15 and a twelve month high of $6.01. The company has a 50-day simple moving average of $2.86 and a 200 day simple moving average of $2.89.</p>
<div class="lb-trans"><p>NRx Pharmaceuticals 的股票在周二的中午交易中上涨了 0.08 美元，达到了 2.47 美元。该股票交易了 244,367 股，而其平均交易量为 489,283 股。该公司的市值为 6926 万美元，市盈率为-1.04，贝塔值为 1.76。NRx Pharmaceuticals 的 12 个月低点为 1.15 美元，12 个月高点为 6.01 美元。该公司的 50 日简单移动平均为 2.86 美元，200 日简单移动平均为 2.89 美元。</p>
</div><p>NRx Pharmaceuticals (NASDAQ:NRXP - Get Free Report) last posted its quarterly earnings data on Friday, November 14th. The company reported ($0.18) earnings per share for the quarter, missing analysts' consensus estimates of ($0.11) by ($0.07). The firm had revenue of $0.24 million for the quarter, compared to analyst estimates of $6.83 million. Equities research analysts forecast that NRx Pharmaceuticals will post -1.75 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>NRx Pharmaceuticals（纳斯达克代码：NRXP - 获取免费报告）最近在 11 月 14 日发布了季度财报。该公司报告本季度每股收益为-0.18 美元，低于分析师共识预期的-0.11 美元，差距为-0.07 美元。该公司本季度的收入为 24 万美元，而分析师预期为 683 万美元。股票研究分析师预测，NRx Pharmaceuticals 在当前财政年度将发布-1.75 美元的每股收益。</p>
</div><h2>Institutional Investors Weigh In On NRx Pharmaceuticals</h2>
<div class="lb-trans"><h2>机构投资者对 NRx Pharmaceuticals 的看法</h2>
</div><p>Several institutional investors have recently bought and sold shares of NRXP. Anson Funds Management LP increased its position in shares of NRx Pharmaceuticals by 535.1% in the first quarter. Anson Funds Management LP now owns 1,179,061 shares of the company's stock worth $2,417,000 after acquiring an additional 993,401 shares in the last quarter. Geode Capital Management LLC boosted its position in NRx Pharmaceuticals by 27.9% during the 2nd quarter. Geode Capital Management LLC now owns 172,255 shares of the company's stock worth $562,000 after purchasing an additional 37,598 shares during the period. Ethos Financial Group LLC purchased a new stake in NRx Pharmaceuticals during the 3rd quarter worth $39,000. One Wealth Management Investment &amp; Advisory Services LLC increased its holdings in NRx Pharmaceuticals by 86.1% in the 3rd quarter. One Wealth Management Investment &amp; Advisory Services LLC now owns 27,991 shares of the company's stock valued at $92,000 after purchasing an additional 12,950 shares in the last quarter. Finally, AdvisorShares Investments LLC raised its position in NRx Pharmaceuticals by 29.7% in the third quarter. AdvisorShares Investments LLC now owns 342,136 shares of the company's stock valued at $1,129,000 after purchasing an additional 78,339 shares during the period. 4.27% of the stock is currently owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>几家机构投资者最近买入和卖出了 NRXP 的股票。Anson Funds Management LP 在第一季度将其在 NRx Pharmaceuticals 的持股增加了 535.1%。Anson Funds Management LP 现在拥有 1,179,061 股该公司的股票，价值 241.7 万美元，此前在上个季度增持了 993,401 股。Geode Capital Management LLC 在第二季度将其在 NRx Pharmaceuticals 的持股增加了 27.9%。Geode Capital Management LLC 现在拥有 172,255 股该公司的股票，价值 56.2 万美元，此前在此期间购买了 37,598 股。Ethos Financial Group LLC 在第三季度购买了 NRx Pharmaceuticals 的新股份，价值 39,000 美元。One Wealth Management Investment &amp; Advisory Services LLC 在第三季度将其在 NRx Pharmaceuticals 的持股增加了 86.1%。One Wealth Management Investment &amp; Advisory Services LLC 现在拥有 27,991 股该公司的股票，价值 92,000 美元，此前在上个季度增持了 12,950 股。最后，AdvisorShares Investments LLC 在第三季度将其在 NRx Pharmaceuticals 的持股增加了 29.7%。AdvisorShares Investments LLC 现在拥有 342,136 股该公司的股票，价值 112.9 万美元，此前在此期间增持了 78,339 股。目前，4.27% 的股票由对冲基金和其他机构投资者持有。</p>
</div><h2>About NRx Pharmaceuticals</h2>
<div class="lb-trans"><h2>关于 NRx Pharmaceuticals</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>NRx Pharmaceuticals, Inc, a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.</p>
<div class="lb-trans"><p>NRx Pharmaceuticals, Inc 是一家临床阶段的生物制药公司，开发用于治疗中枢神经系统疾病的新型治疗药物，包括自杀性抑郁症、创伤后应激障碍和慢性疼痛。其产品包括 NRX-101（D-氨基酸/氟哌噻吨），这是一种口服固定剂量的 D-氨基酸和氟哌噻吨的组合，获得了食品和药物管理局指定的自杀治疗耐药性双相抑郁症的突破性疗法；以及 NRX-100（氯胺酮），该药物已获得 FDA 快速通道认证，用于治疗伴有急性自杀意念和行为的重度双相抑郁症。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>特色文章</h2>
</div><ul>
<li>Five stocks we like better than NRx Pharmaceuticals</li>
<li>The 3 Best Retail Stocks to Shop for in August</li>
<li>These Are the Hottest Upgrades From the Q3 Reporting Cycle</li>
<li>Using the MarketBeat Dividend Tax Calculator</li>
<li>Fossil Stock Is Quietly Surging—Insiders Just Made Big Bets</li>
<li>ETF Screener: Uses and Step-by-Step Guide</li>
<li>Why Bitcoin ETFs Like IBIT May Be Set to Surge in 2026</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票超过 NRx Pharmaceuticals</li>
<li>8 月值得关注的三只最佳零售股票</li>
<li>这些是第三季度报告周期中最热门的升级</li>
<li>使用 MarketBeat 股息税计算器</li>
<li>Fossil 股票悄然上涨——内部人士刚刚进行了大额押注</li>
<li>ETF 筛选器：用途和逐步指南</li>
<li>为什么像 IBIT 这样的比特币 ETF 可能会在 2026 年激增</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TlJYUA" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=NRXP"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in NRx Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 NRx Pharmaceuticals 吗？</h2>
</div><p>Before you consider NRx Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 NRx Pharmaceuticals 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and NRx Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 NRx Pharmaceuticals 并不在名单上。</p>
</div><p>While NRx Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 NRX Pharmaceuticals 目前在分析师中被评为适度买入，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

NRX Pharmaceuticals（NRXP）的 “买入” 评级在 D. Boral Capital 被再次确认